The awards are conditional on your meeting certain obligations and deliverables, including:
Investigators may apply from accredited academic medical centers, research institutions or universities in the U.S. and U.S. territories. Institutions must provide the necessary facilities and infrastructure for the research, and accept the conditions of the award, including the Budget & Use of Funds. They must also assure compliance with the prevailing national guidelines for animal and human studies and provide proper oversight of the Grant funds.
Sponsoring institutions must safeguard the rights and welfare of individuals who participate as subjects in research activities by reviewing proposed activities through an Institutional Review Board (IRB) as specified by the U.S. Department of Health and Human Services Office for Human Research Protections, HHS OHRP. Additionally, the Grantee’s institution must assure appropriate governance of animal studies. IRB approval and IACUC numbers are not required at the time of application, but must be provided for final signature of the Grant Agreement, which will be sent to Grantees shortly after they have been selected.
Additionally, sponsoring institutions must adhere to current U.S. Department of Health and Human Services guidelines regarding financial conflict of interest, recombinant DNA, and research misconduct.
The call for applications for the Harrington Rare Disease Scholar Award opens May 24, 2017. For more information, please refer to the Dates to Know box or email HDIQuestions@HarringtonDiscovery.org.
Members of Harrington Discovery Institute, Takeda, and the Rare Disease Scientific Advisory Board involved in reviewing applications for the Harrington Rare Disease Scholar Award are required to complete mutual Confidentiality & Disclosure Agreements with Harrington Discovery Institute.
Non-public applicant information is always kept confidential (and limited in distribution to the reviewers and Harrington Discovery Institute administrative team). The abstract summary, including the applicant’s name and institutional affiliation, for those selected as Harrington Rare Disease Scholars, may be used by Harrington Discovery Institute for publicity and marketing purposes (on the Harrington Discovery Institute website, news releases, etc.) at Harrington Discovery Institute's sole discretion.
Applicants acknowledge that University Hospitals Health System may conduct research that is related to or competitive with proposals submitted by applicants, but University Hospitals Health System commits not to use information submitted by applications in connection with such research.
The review panel will consist of subject matter experts with specialized scientific expertise in the area(s) designated in the application, as well as seasoned professionals with expertise in drug development and commercialization.
Projects will be assessed based on:
The Rare Disease Scientific Advisory Board at Harrington Discovery Institute will make the final selection of winners.
Applicants who fail to fill out their applications by the deadline and/or in accordance with the detailed instructions are subject to disqualification at the outset of the review period or any time during the review period.
Barring any unforeseen delays, winners will be announced in February 2018.
Harrington Discovery Institute is unable to provide reviewers’ comments or feedback.
Yearly renewal of the award is dependent on timely submission of a written progress report as well as attendance at Harrington Discovery Institute’s Annual Scientific Symposium.
A significant change in the project scope or work should be discussed with Harrington Discovery Institute’s Program Director and Chief Scientific Officer.
Awards may be transferred to another institution that agrees to assume the Policies, Terms & Conditions of the agreement. Permission to transfer the award to another institution must be obtained from Harrington Discovery Institute’s Chief Scientific Officer.
Awards are funded by Harrington Discovery Institute, on the recommendations of the Rare Disease Scientific Advisory Board. Harrington Discovery Institute staff will assure compliance with program policies and will be responsible for all administrative matters.
The Principal Investigator and his or her institution are solely responsible for execution of the project, including compliance with all relevant Federal and State laws and guidelines.
Harrington Discovery Institute reserves the right to refine and amend policies as required.
Questions should be directed to HDIquestions@HarringtonDiscovery.org.
Harrington InnovationSupport Center